Scarica l'app Stockscreener
2.65
1.49%
-0.04
Dopo l'orario di chiusura:
2.65
Precedente Chiudi:
$2.69
Aprire:
$2.71
Volume 24 ore:
30,777
Relative Volume:
0.02
Capitalizzazione di mercato:
$12.63M
Reddito:
$14.50M
Utile/perdita netta:
$-15.41M
Rapporto P/E:
-3.7324
EPS:
-0.71
Flusso di cassa netto:
$-13.04M
1 W Prestazione:
-8.62%
1M Prestazione:
+5.58%
6M Prestazione:
+0.76%
1 anno Prestazione:
-22.51%
Intervallo 1D:
$2.65
$2.71
Intervallo di 1 settimana:
$2.52
$2.90
Portata 52W:
$1.91
$48.79
Vivos Therapeutics Inc Stock (VVOS) Company Profile
Nome
Vivos Therapeutics Inc
Settore
Industria
Telefono
(866)908-4867
Indirizzo
7921 SOUTHPARK PLAZA,, LITTLETON
Vivos Therapeutics Inc Borsa (VVOS) Ultime notizie
Vivos Therapeutics’ stock soars as sleep apnea device gets regulatory clearance - MSN
Vivos Therapeutics Secures FDA Clearance for Pediatric OSA Device, secures new AMA CPT Codes - Proactive financial news
Vivos Granted Reimbursement Codes for Oral Appliances for OSA - Sleep Review
Vivos secures new AMA medical codes for OSA devices - Investing.com
Pre-Market Momentum Builds For Vivos Therapeutics (VVOS) Following Key Developments - Stocks Telegraph
Vivos secures new AMA medical codes for OSA devices By Investing.com - Investing.com South Africa
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association - The Manila Times
Vivos Therapeutics wins approval for streamlined insurance reimbursement for sleep apnea treatment - Proactive Investors UK
Balance Sheet Insights: Vivos Therapeutics Inc (VVOS)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Stock Market Recap: Vivos Therapeutics Inc (VVOS) Concludes at 3.08, a -4.35 Surge/Decline - The Dwinnex
Vivos surges on FDA nod for pediatric sleep apnea device - MSN
You might want to take a look at Vivos Therapeutics Inc (VVOS) now - SETE News
Vivos Therapeutics announces $4.3 million stock sale By Investing.com - Investing.com Canada
Vivos Therapeutics announces $4.3 million stock sale - Investing.com
VVOS’s price-to-cash ratio: How it affects the stock’s valuation. - US Post News
Vivos Therapeutics Shares Drop 27% After Pricing of Common Stock Offering - MarketWatch
Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today - Benzinga
Nasdaq Surges 400 Points; US Jobless Claims Fall To 219,000 - Benzinga
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - StockTitan
Vivos Therapeutics raises $4.3 from institutional investors - Proactive financial news
Nvidia, T-Mobile US, Vivos Therapeutics, SoFi Technologies, Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Vivos Therapeutics surges on FDA approval for youth sleep apnea treatment device - Mugglehead
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring - ForexTV.com
S&P 500 Industrials [Sector] (SRIN) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX 60 Equal Weight Index (TXEW) QuotePress Release - The Globe and Mail
TSX Metals and Mining Capped Index (TTMN) QuotePress Release - The Globe and Mail
TSX Cannabis Index (XCAN) QuotePress Release - The Globe and Mail
Company’s Banking Shares: Up -92.74% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
Vivos Therapeutics rises on FDA approval for pediatric sleep apnea device - XM
What's Going On With TG Therapeutics Stock Wednesday? - Benzinga
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children - Benzinga
Vivos Therapeutics Shares Rally on FDA Clearance for Pediatric Sleep Apnea Treatment - MarketWatch
Vivos Therapeutics’ oral device approved by FDA for pediatric sleep apnea treatment - Proactive Investors UK
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Vivos (VVOS) Stock Rallies In Pre-Hours Trading Following Key Regulatory Approval - Stocks Telegraph
Vivos gains FDA nod for child OSA treatment device - Investing.com
Vivos receives FDA 510k clearance to treat pediatric sleep apnea, snoring - TipRanks
Target Hospitality Corp. Forecasted to Post FY2025 Earnings of $0.39 Per Share (NASDAQ:TH) - Defense World
Research Analysts Set Expectations for Huntington Ingalls Industries, Inc.’s Q2 2025 Earnings (NYSE:HII) - Defense World
Upbound Group, Inc. (NASDAQ:UPBD) Receives $40.25 Consensus Price Target from Brokerages - Defense World
Verint Systems Inc. (NASDAQ:VRNT) Short Interest Up 29.6% in August - Defense World
Los Angeles Capital Management LLC Sells 4,000 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Los Angeles Capital Management LLC Grows Position in TPI Composites, Inc. (NASDAQ:TPIC) - Defense World
Vivos Therapeutics announces new equity incentive plan and executive agreements - Investing.com
Vivos Therapeutics Enhances Incentives and Executive Pay Structure - TipRanks
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story - Simply Wall St
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update - Defense World
3 Trending Biotech Penny Stocks - 24/7 Wall St.
VVOS Stock Earnings: Vivos Therapeutics Beats EPS, Beats Revenue for Q2 2024 - MSN
Ascendiant sees 180% upside in Vivos Therapeutics shares amid revenue rebound - Investing.com Canada
Vivos Therapeutics Inc Azioni (VVOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.47%
1.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):